Suchergebnisse - "Telli, Tugce"

PubPharm (17)

1

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel : The PACAP Study

enthalten in: European urology oncology | 2024

von Flippot, R. | Telli, T. | Velev, M. | +26

2

Imaging of Cardiac Fibrosis : How Far Have We Moved From Extracellular to Cellular?

enthalten in: Seminars in nuclear medicine | 2024

von Telli, T. | Hosseini, A. | Settelmeier, S. | +6

3

High AST and the Presence of Liver Metastases May Guide for the Need for FDG PET in Advanced Prostate Cancer Patients

enthalten in: ResearchSquare.com | 2024

von Telli, T. | Tuncel, M. | Karabulut, E. | +4

4

What Role Does PET/MRI Play in Musculoskeletal Disorders?

enthalten in: Seminars in nuclear medicine | 2023

von Telli, T. | Desaulniers, M. | Pyka, T. | +7

5

Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy

enthalten in: Journal for immunotherapy of cancer | 2023

von Handke, A. | Kesch, C. | Fendler, W. | +10

6

Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors

enthalten in: Cancers | 2023

von Weber, M. | Telli, T. | Kersting, D. | +1

7

Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with 177 Lu-PSMA-617. A single-center prospective observational study

enthalten in: The Prostate | 2023

von Telli, T. | Tuncel, M. | Karabulut, E. | +4

8

Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2023

von Seifert, R. | Telli, T. | Hadaschik, B. | +3

9

Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2023

von Seifert, R. | Telli, T. | Opitz, M. | +8

10

Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with177 Lu‐PSMA‐617. A single‐center prospective observational study

enthalten in: The Prostate | 2023

von Telli, T. | Tuncel, M. | Karabulut, E. | +4